HTG Molecular Diagnostics
Tucson
About HTG Molecular Diagnostics
HTG Molecular Diagnostics is a provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company's NGS-adapted chemistry and HTG EdgeSeq technology automate sample processing and can swiftly, reliably, and concurrently profile hundreds or thousands of molecular targets utilizing a very little quantity of biological material, in liquid or solid form. Its products comprise equipment, consumables, and software that work together to form the HTG EdgeSeq platform. The HTG EdgeSeq platform automates the company's menu of HTG EdgeSeq molecular profiling panels, which use genomic sequencing techniques to swiftly provide gene expression data for clients utilizing its streamlined approach. HTG Molecular Diagnostics was established in 1997 by Bruce E. Seligmann in Tucson, Arizona.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $106.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2022)
- Ticker: nasdaq:HTGM
- Website: htgmolecular.com
- Phone: 5205472837
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/htg-molecular-diagnostics-166205 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.